Page 19 - rp-may-2020

FIRST-LINE
FOR A
REASON
1
When it comes to treating OA flare-up pain with en it comes to treating OA flare-up pain with
oral therapyal therapy
, provide patients with balanced ovide patients with balanced
pain relief.
1-7
Nurofen 400 Double Strengthrofen 400 Double Strength
offers the fers the
same low risk of GI side effects as paracetamole low risk of GI side effects as paracetamol
^5-7
with the powerful pain relief of an NSAID for up h the powerful pain relief of an NSAID for up
to 8 hours, in just 1 tablet.ours, in just 1 tablet.
2-4
From 1 June m 1 June
2020, modified-, modified-
release (MR) ase (MR)
paracetamol acetamol
will be up-l be up-
scheduled to eduled to
S3 (Pharmacist Pharmacist
Only).ly).
1
The TGA concludes TGA concludes
there are significant are significant
health risks lth risks
associated with ciated with
the misuse of MR isuse of MR
paracetamol. acetamol.
1
Up-scheduling scheduling
preserves erves
accessibility and essibility and
gives pharmacists s pharmacists
more opportunity opportunity
to counsel patients ounsel patients
about accurate ut accurate
dosing.ing.
1
Be prepared to repared to
discuss changes ss changes
with patients and patients and
take the opportunity the opportunity
to reassess their assess their
OA flare-up pain flare-up pain
management.agement.
Contact your tact your
RB representative epresentative
for support for support for
your pharmacy. pharmacy.
MAKE THE MOVE VE
TO NUROFEN
Reference: 1.
Australian Government. nment.
Department of Health. Therapeutic Goods
Administration. Changes to the way modified
release paracetamol products are supplied:
questions and answers. Available at: vailable at:
https://www.tga.gov.au/.tga.gov.au/
changes-way-modified-release-paracetamol-
products-are-supplied-questions-and-answers
^When taken as directed in an over-the-counter setting in patients without contraindications/precautions. -the-counter setting in patients without contraindications/precautions.
GI:
gastrointestinal. osteoarthritis.
OA:
osteoarthritis. non-steroidal anti-inflammatory drug.
NSAID:
non-steroidal anti-inflammatory drug.
Nurofen 400 Double Strength contains 400mg ibuprofen. For the temporary relief of pain.y relief of pain.
References: 1.ces: 1.
The Royal Australian College of General Practitioners. yal Australian College of General Practitioners.
Guideline for the management of knee and hip osteoarthritis.ne for the management of knee and hip osteoarthritis.
2nd edn. East n. East
Melbourne, Vic: RACGP, 2018. Mehlisch DR rne, Vic: RACGP, 2018. Mehlisch DR
2.
et al. Clin Therlin Ther
2010;32(6):1033-1049. Malmstrom K 2(6):1033-1049. Malmstrom K
3.
et al. Clin Therlin Ther
1999;21(10):1653-1663. 21(10):1653-1663.
4.
Malmstrom K trom K
et al. Clin Therlin Ther
2004;26(5):667-679. 26(5):667-679.
5.
Moore N
et al. Clin Drug Investlin Drug Invest
1999;18:89–98. 18:89–98.
6.
Rampal P l P
et al. J Int Med Resnt Med Res
2002;30:301–308. Varrassi G :301–308. Varrassi G
7.
et al. Adv Therdv Ther
2019; doi: 10.1007/s12325-019-01144-9. oi: 10.1007/s12325-019-01144-9.
®NUROFEN is a registered trademark of the Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia. FEN is a registered trademark of the Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia.
Prepared d
Februaryry
2020.
FIRST-LINE
FOR A
REASON
1
Wh
or
, pr
pain relief.
1-7
Nu
of
sam
^5-7
wit
to 8 h
2-4
Fro
2020
rele
par
wil
sch
S3 (
On
1
The
there
hea
asso
the m
par
1
Up-
pres
acc
give
more
to c
abo
dos
1
Be p
discu
with
take
to re
OA
man
Con
RB r
for
your
MAKE THE MO
TO NUROFEN
Reference: 1.
Australian Gover
Department of Health. Therapeutic Goods
Administration. Changes to the way modified
release paracetamol products are supplied:
questions and answers. A
https://www
changes-way-modified-release-paracetamol-
products-are-supplied-questions-and-answers
^When taken as directed in an over
GI:
gastrointestinal.
OA:
NSAID:
Nurofen 400 Double Strength contains 400mg ibuprofen. For the temporar
Referen
The Ro
Guideli
2nd ed
Melbou
2.
et al. C
2010;3
3.
et al. C
1999;
4.
Malms
et al. C
2004;
5.
Moore N
et al. C
1999;
6.
Rampa
et al. J I
2002;30
7.
et al. A
2019; d
®NURO
Prepare
Februa
2020.